Clinical Trial Update: A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the safety and efficacy of aliskiren/hydrochlorothiazide combinations (300/12.5 mg and 300/25 mg) compared with aliskiren 300 mg in hype…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• HYDROCHLOROTHIAZIDE (hydrochlorothiazide)
• Tekturna (aliskiren) (aliskiren)

Snippet

Sponsor: Novartis | Conditions: Hypertension | Phase 3 | Status: COMPLETED